Section Arrow
Quote
RNAZ.NASDAQ
- TransCode Therapeutics Inc
Quotes are at least 15-min delayed:2025/11/19 11:06 EST
Regular Hours
Last
 9.2799
+0.2499 (+2.77%)
Day High 
9.2799 
Prev. Close
9.03 
1-M High
15.333 
Volume 
3.14K 
Bid
8.86
Ask
9.09
Day Low
8.9 
Open
9.01 
1-M Low
8.41 
Market Cap 
8.28M 
Currency USD 
P/E 0 
%Yield -- 
10-SMA 9.17 
20-SMA 10.53 
50-SMA 11.49 
52-W High 468.44 
52-W Low 6.14782 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-61.43/-8.96
Enterprise Value
8.28M
Balance Sheet
Book Value Per Share
6.70
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NUVBNuvation Bio6.55+1.75+36.46%-- 
ASBPAspire Biopharma Holdings Inc.0.0974-0.0083-7.85%-- 
OLMAOlema Pharmaceuticals22.53+2.39+11.87%-- 
CYPHCypherpunk Technologies Inc.3.07+0.1+3.37%-- 
KZIAKazia Therapeutics Limited7.98+2.22+38.54%-- 
Quotes are at least 15-min delayed：2025/11/19 11:06 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.